Filing of an Emergency Use Authorization (EUA) for lenzilumab as treatment of hospitalised, hypoxic COVID-19 patients plans for end of May

Phase III trial (n=520) showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need of intermittent mandatory ventilation, vs. patients on placebo and other treatments.

SPS commentary:

These data for this agent which targets GM-CSF, a cytokine linked to poor outcomes in COVID-19 patients, will support the submission of applications for EUA to the FDA and conditional marketing authorisation in UK and the European Union.

Biospace Inc.